Physician profile
Stephen Carter
NPI 1013909134
$14,346.89
in general payments reported to CMS, 2019-2025
38 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,817 · 2020: $1,426 · 2021: $1,360 · 2022: $1,384 · 2023: $2,843 · 2024: $3,087 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,246 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,246.09 |
| Education | $113.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,750.80 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $2,023.87 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Stability Biologics, LLC | $1,655.48 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $1,093.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $866.48 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $587.68 | 2019-2025 | Epsolay, Aklief, Nemluvio |
| Lilly USA, LLC | $565.11 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $547.27 | 2019-2025 | |
| Ucb, INC. | $502.92 | 2019-2025 | Bimzelx |
| Amgen INC. | $442.90 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $433.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $426.23 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $359.25 | 2021-2024 | Adbry |
| Dermira, INC. | $289.82 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $251.15 | 2019-2025 | Jublia, Arazlo, Cabtreo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $249.11 | 2023-2025 | Opzelura |
| Epi Health, LLC | $212.18 | 2019-2022 | |
| Pfizer INC. | $169.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $127.61 | 2023-2024 | Sotyktu |
| Organon LLC | $100.94 | 2023-2025 | Hadlima, Vtama |
| Journey Medical Corporation | $75.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.88 | 2024-2025 | Spevigo |
| Biofrontera INC. | $58.20 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $57.85 | 2019-2023 | Klisyri |
| Mission Pharmacal Company | $57.07 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $51.59 | 2025 | Acthar |
| Botanix Sb INC | $45.25 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $41.54 | 2023 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $41.30 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $39.02 | 2020-2021 | |
| Convatec INC. | $34.12 | 2025 | |
| Ani Pharmaceuticals, INC. | $30.80 | 2024 | Purified Cortrophin Gel |
| Celgene Corporation | $24.12 | 2019 | |
| Cipher Pharmaceuticals US LLC | $17.01 | 2025 | Spinosad, Natroba |
| Arcutis Biotherapeutics, INC. | $15.15 | 2023 | |
| Verrica Pharmaceuticals INC. | $14.36 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Prugen, INC. Pharmaceuticals | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.